Gooseneck faucets, shallow sinks behind deadly hospital infection outbreak
Canadian Press, December 2008
TORONTO — It's a cruel irony that in a setting where clean hands are critical, the sinks turned out to be the problem.
The design and placement of hand hygiene stations in hospital rooms housing transplant patients was responsible for an outbreak of bacterial infections that left 12 patients dead and two dozen others sickened, Toronto doctors who cracked the mystery behind how the bugs were spreading reveal in a new study.
The outbreak is history, having occurred - without much public attention - between December 2004 and March 2006 at Toronto General Hospital.
But the infection control specialists who tracked down the source of the multi-drug resistant bug involved in the outbreak believe other hospitals could learn from the tragedy that befell their transplant unit.
"The main reason that we published this is because we thought that this was an important lesson. People need to know this," says Dr. Michael Gardam, senior author of the article, published in the January issue of the journal Infection Control and Hospital Epidemiology.
"The message from this for us was that hand hygiene sinks are obviously really important - and they have to be the right design. And they have to be in the right place. And they can't be splashing."
The bug behind the outbreak was Pseudomonas aeruginosa, a moisture lover. It thrives in drains, where it forms what scientists call biofilms. The rest of us call that slime, sludge or gunk.
Pseudomonas bacteria are everywhere. In fact, the bug would probably be found in most household drains if anyone bothered to check. But no one would. The bacteria pose no threat to healthy people.
But it's a different story for patients who have just received an organ transplant. These patients are on drugs that suppress their immune systems so their body doesn't reject the donor organ and their systems are already weakened by whatever caused the need for the transplant.
In these and other seriously ill hospitalized patients, Pseudomonas can trigger skin, wound or bloodstream infections or pneumonia. And if the bacteria become resistant to antibiotics - as bacteria in hospitals are wont to do - the infections they cause can be challenging to treat.
"You had to be sick to get the infection. The infection makes you sicker," explains Gardam, head of infection control for the University Health Network (Toronto General is one of its three hospitals) and director of infectious diseases prevention and control at the Ontario Agency for Health Protection and Promotion.
"And when you've got an organism that is resistant to everything, there's not a lot of treatment we can offer you. That was basically the situation we were in."
When it became apparent transplant patients in the hospital's medical and surgical intensive care unit, transplant step-down unit and transplant ward were becoming infected with a multi-drug resistant strain of Pseudomonas, the infection control team began an intensive investigation to determine how patients and bugs were coming into contact.
Initially the cases were patients who were located near one another, leading infection control to suspect health-care workers were transferring the bugs on their hands. But when other patients started cropping up, it became apparent the answer wasn't that simple.
In all, 36 patients were either infected or colonized with the outbreak strain. (Colonized means a person is carrying the bacteria on the skin or in cavities like the nostrils, but the bacteria isn't causing illness.)
Two-thirds of the patients were infected and 17 died. A retrospective review of the deaths concluded the outbreak strain killed five patients and contributed to the deaths of seven others, the article says.
Given Pseudomonas aeruginosa's fondness for moisture, the infection control team began testing sinks. Bacteria were found in some but not others, and in some it was only found intermittently.
"It was really only when we said: 'OK, we're going to test every single bloody sink multiple times' that we started finding it in some of the sinks. It was never in all of the sinks. It was only ever in some of the sinks," Gardam says.
And how it was getting from drains to patients wasn't clear. "This was the kind of thing that kept us all up at night," he admits.
The painstaking investigation led to the conclusion that the design of the sinks was responsible.
Each single-patient room in the medical and surgical intensive care unit had its own hand hygiene station. They were located just over a metre from the head of the patient's bed and adjacent to a counter top health-care workers used to prepare medication and sterile dressings for the patient.
The sinks had shallow basins and high, gooseneck spouts that flowed directly into the drain below. Because of that design, the pressure from the spout splashed water out of the drain, spraying nearby surfaces.
If the drain contained Pseudomonas, it meant that using the sink ended up showering the counter top and maybe even the bed with droplets of bacteria-laced water.
The infection control team proved this using a CSI-like approach. Hospital room surfaces were covered with black paper, a fluorescent gel was injected deep into the drain and someone washed his or her hands.
Using an ultraviolet light in the blacked out room, the investigators saw fluorescent splatter had travelled at least one metre - as far as the head of the bed and onto the preparatory counter. The authors believe smaller droplets probably carried further.
On the strength of that evidence, the hospital took the step of removing the sinks. No new cases were reported after that. New sinks with a different design were installed, with splash guards between the sink and the treatment preparation area. Testing showed the splatter problem had been solved.
Dr. Andrew Simor, an infection control expert at Toronto's Sunnybrook Health Sciences Centre, says the outbreak report identifies two issues of which hospitals should take note.
While single rooms with sinks are ideal for cutting the risk patients will pick up hospital-acquired infections, those sinks shouldn't be located too close to beds or treatment preparation areas.
And the design of sinks is critical. Simor says hospitals can't prevent biofilms from forming in drains, despite their best efforts. But by limiting the potential for splashing, they can perhaps keep those biofilms where they can't hurt patients.
"We're always learning," says Simor, who heads the microbiology department of his hospital.
"And that's why this was an instructive report. Because it does remind us that it's not just as clear cut as having a private room with a sink."
Gooseneck faucets, shallow sinks behind deadly hospital infection outbreak
C. diff Epidemic Likely to Get Worse
by Charlene Laino
WebMD Health News Reviewed by Louise Chang, MD
Oct. 30, 2008 (Washington, D.C.) -- The nation's epidemic of the nasty superbug Clostridium difficile, or C. diff, will likely get worse before it gets better, says a panel of experts.
Cases of the potentially dangerous diarrhea bug have now been seen in all 50 states, says L. Clifford McDonald, MD, of the CDC's Division of Healthcare Quality and Promotion. And "we haven't hit bottom yet," says Lance Peterson, MD, of the Evanston Northwestern Healthcare Research Institute in Illinois.
Most cases of C. diff occur in people taking antibiotics. Spores enter the body through the mouth, which is the entryway for the gastrointestinal tract. The overgrowth of the C. diff bacteria in the colon, or large intestine, can cause diarrhea, which is often severe and accompanied by intestinal inflammation known as colitis.
Antibiotics can kill "good" bacteria in the colon that keeps C. diff at bay, explains M. Lindsay Grayson, MD, vice chairman of the committee that chose which studies to highlight at the meeting and an infectious diseases specialist at Austin Health in Melbourne, Australia.
Infection often runs rampant in hospitals and nursing homes, where patients and health care workers are in close proximity. Typically, the bug can't be wiped out by standard cleaning agents, he tells WebMD.
The experts spoke here at a joint meeting of the American Society for Microbiology and the Infectious Diseases Society of America.
Deaths Up Fivefold
Hospital discharge data reveal a fourfold increase in C. difficile rates since 2001, according to McDonald. Associated deaths have increased fivefold, he says.
Overall, C. diff is responsible for tens of thousands of cases of diarrhea and at least 5,000 deaths a year, according to the CDC.
The Infectious Diseases Society of America and the Society of Healthcare Epidemiology of America have published guidelines aimed at reducing the spread of the superbug. Among its recommendations are to avoid overuse of antibiotics, use bleach to clean surfaces during outbreaks, don gowns and gloves when caring for patients, and follow strict hand washing and other good hygiene practices.
The antibiotics vancomycin and metronidazole are typically used to treat the infection, but the drugs are failing to help many patients, especially those with repeat bouts, says Dale Gerding, MD, of Hines VA Hospital in Chicago.
"We've had the same therapies for 30 years and new ones are desperately needed," he tells WebMD.
One procedure that does seem to work, but has been slow to catch on in the U.S., is a "fecal transplant," Gerding says.
Doctors obtain a stool sample from a healthy relative of the patient, typically a spouse, filter the sample, and infuse it into the C. difficile patient, typically via a nasal tube.
The idea is that the fresh stool will restore whatever bacteria were depleted from the infected person's intestines by antibiotic treatment, Gerding says.
"It's highly effective, with success rates of about 90%. But hospital safety boards are reluctant to approve its use as they fear other pathogens could also be introduced [into the patient]," he says.
In Europe, especially Scandinavia, the procedure has gained better acceptance, Gerding says
Nov. 11, 2008
AUSTIN, Texas, Nov 11, 2008
Consumers Union called on hospitals today to take more aggressive steps to protect patients from Clostridium difficile (C.-diff.) infections in light of a new report showing that they are much more common than previous estimates had indicated. As the rate of hospital acquired C.-diff. infections has jumped in recent years, an increasing number of patients have developed antibiotic-resistant strains of the infection that are more difficult to treat and more deadly.
The report released by the Association for Professionals in Infection Control and Epidemiology (APIC) found that 13 out of every 1,000 patients or approximately 7,178 inpatients on any one given day were infected or colonized with C.-diff (94.4 percent were infected). The rate is 6.5 to 20 times higher than previous incidence estimates that were based on more limited data. The report estimated that on any given day these infections cost between $17.6 million to $51.5 million and kill between 165 and 438 patients.
The APIC report is based on a survey of infection control professionals from 648 health care facilities throughout the country who collected data about all of their patients with C.-diff. infections on one day between May and August 2008.
"C-diff. infections are much too common in our nation's hospitals and threaten the health of thousands of patients every year," said Lisa McGiffert, Director of Consumers Union's Stop Hospital Infections Campaign ( www.StopHospitalInfections.org). "Most hospitals aren't doing enough to protect patients from these deadly, preventable infections."
C.-diff. bacteria is released into the hospital environment in feces. It is found on surfaces throughout hospitals and nursing homes and can be spread to patients through hand contact. In one study, C.-diff. was found on the hands of nearly 60 percent of doctors and nurses caring for infected patients. Studies have found C.-diff. contamination of almost all objects in the hospital environment, ranging from stethoscopes and blood pressure cuffs to mops.
When patients undergo antibiotic therapy, beneficial bacteria in the colon are killed off, but C.-diff. survives and multiplies. The bacteria release toxins that cause inflammation and damage the mucosal lining of the colon leading to severe diarrhea. An antibiotic-resistant strain of C.-diff. has developed in recent years that can result in colitis, sepsis, and death. Elderly patients, patients with severe underlying illness, and patients undergoing immunosuppressive therapy are at higher risk of becoming infected since their immune response to the bacteria and its toxins is diminished.
According to the federal Agency for Healthcare Improvement's Healthcare Cost and Utilization Project, the number of hospital patients with C.-diff. infections more than doubled between 2001 and 2005 to 301,200 patients. As infection rates have increased, so have mortality rates. According to data from death records and the National Inpatient Sample, fatality rates rose from 1.2% in 2000 to 2.2% in 2004, indicating that C.-diff. infections are becoming more dangerous and deadly.
APIC's survey found that 54.4 percent of patients with C.-diff. were identified within 48 hours of admission and that most were admitted to the hospital already infected. However, APIC estimates that 72.5 percent of the patients with C.-diff. infections developed them as a result of exposure to bacteria in a healthcare facility. In other words, many patients who were admitted with an infection picked it up during a previous stay at a hospital or nursing home.
The most basic way to prevent infections is to keep patients from being colonized by C.-diff. The Center for Disease Control and Prevention's (CDC) Guidelines for Infection Control in Health Care Facilities notes that proper hand hygiene is the single most important factor in protecting patients from C.-diff. and other hospital-acquired infections. To complicate matters, the CDC advises that hands must be washed with soap and water when caring for C.-diff patients, as the commonly used alcohol-based hand gel is ineffective against this bacteria. Unfortunately, studies have repeatedly shown that handwashing compliance rates in hospitals are generally less than 50 percent. Other key infection control strategies include using contact precautions, including gloves and gowns with C.-diff. patients and separating them from other patients.
Improved cleanliness in hospital wards is also necessary to limit the spread of C.-diff. Use of a hypochlorite (bleach) cleaning solution is the most effective way to eliminate the bacteria. Hospitals that have stepped up efforts to more thoroughly clean hospital wards have effectively controlled the spread of C.-diff. However, reports show that hospital cleaning budgets are being cut every year and that these reduced numbers of cleaning staff are often inadequately trained.
Finally, since being on antibiotics is a risk factor for C.-diff., hospitals that restrict the use of the type of antibiotics frequently associated with these infections have had more success in protecting patients.
"Health care consumers need to be aware that most U.S. hospitals are not consistently following basic infection control practices against C.-diff.," said McGiffert. "Patients are already having to remind doctors to wash their hands, but they shouldn't have to bring bleach with them to make sure their rooms are clean. Hospitals need to make sure that rooms are properly disinfected and that staff are following strict infection control practices at all times."
Consumers Union, publisher of Consumer Reports, is an independent, nonprofit testing and information organization serving only the consumer. We are a comprehensive source of unbiased advice about products and services, personal finance, health, nutrition, and other consumer concerns. Since 1936, our mission has been to test products, inform the public, and protect consumers. www.StopHospitalInfections.org, a project of Consumers Union, advocates for public disclosure of hospital-acquired infection rates.
SOURCE Consumers Union
Copyright (C) 2008 PR Newswire. All rights reserved
by Dr. Ranit Mishori
A few years ago, I began noticing an unusual number of patients coming in with what they described as spider bites. In clinics and emergency rooms across the U.S., colleagues were seeing it, too: Young people and old, male and female, complaining about a skin sore not unlike a pimple, often red and swollen, sometimes oozing and painful. The only thing was, very few of these patients recalled being bitten by a spider or any other kind of insect.
That’s because, in most of these cases, it wasn’t an insect. But it was a bug—a bacterium called methicillin-resistant Staphylococcus aureus, better known to most of us now as MRSA. These patient complaints were clear signs of what is now a MRSA epidemic.
According to a recent article in the Journal of the American Medical Association, MRSA caused more than 94,000 life-threatening infections and nearly 19,000 deaths in the U.S. in 2005. One study in The New England Journal of Medicine found MRSA 59% of the time when adults came to emergency rooms with skin infections.
MRSA is not new. It has been plaguing our hospitals for decades. It kills by infecting the blood and lungs of very sick patients or those recovering from surgery. But at least doctors knew—or thought—that if you weren’t a hospital patient in weakened condition, MRSA wasn’t going to find you.
“That is no longer true,” says Dr. Robert Daum, a pediatrician and infectious-diseases specialist at the University of Chicago. “Hospital transmission is not what’s driving the epidemic disease we see everywhere.” New strains of MRSA have been born outside hospital walls and are finding anybody and everybody. That includes, says Dr. Rachel Gorwitz of the Centers for Disease Control and Prevention, “otherwise healthy people in the community, including children.”
Consider Susan Wagoner, 49, a businesswoman from Scottsdale, Ariz. MRSA first appeared as a small abscess on her upper leg. Even though she was treated with antibiotics, the abscess grew larger, and then another one developed elsewhere. The pain became excruciating. As weeks turned into months, her illness forced Wagoner to quit her job, and she says, “I began looking into funeral arrangements.”
Grant Hill, the NBA all-star, contracted MRSA a few years ago as a skin infection near his ankle, and he had to spend a week in the intensive-care unit. “I was lucky to survive,” Hill says.
Not so lucky was an 18-month-old in Chicago named Simon Sparrow, in good health before MRSA got into his lungs. Once it took hold there, even the most aggressive treatment could not rescue the toddler.
These new strains of MRSA—not all as deadly as the one that afflicted Simon—are showing up all over the community: in homes, schools, gyms, military bases, prisons, or any place people get in close proximity with each other. They are transmitted through skin-to-skin contact with uncovered infections, such as shaking hands or bumping up in a football game. MRSA also can spread by sharing objects that are contaminated: towels, clothing, and razors. Indeed, the pattern of infection has earned this variant of the bug a new name: CA-MRSA, for community-associated.
The infection usually shows up as a skin sore. At that point, it’s generally not life-threatening and can be treated by draining the pus, with or without antibiotics. The only problem is that the antibiotics used for most bacterial infections won’t work.
It’s the R in MRSA, which stands for “resistant,” that tells the story. Just after antibiotics were introduced, tiny organisms—Staphylococcus aureus—became “immune” to our first line of antibiotic drugs. These variants survived, thrived, and spread. “Staph Aureus is a very smart bug,” says Dr. Daum. “It figured out every antibiotic we humans have thrown at it and has developed resistance mechanisms to them one by one.”
The nightmare scenario is a world in which we don’t have a pharmaceutical answer for some of the most common germs making us sick. Our experience with MRSA and other infections suggests we’ve taken a step or two in that direction. The current epidemic, says Dr. Daum, has put “tremendous pressure on our antibiotic treatment armamentarium.”
Still, it is way too soon to panic. In most cases, doctors can find drugs that kill the bug. Some—such as Bactrim, clindamycin, and tetracycline—haven’t commonly been used to treat staph infections. There’s also a range of super-powerful antibiotics that have been used successfully in hospitals.
Yes, bugs are smart, and we can’t change that. But the resistance of bacteria also stems from human misuse. We all know people who want to take antibiotics even though their infection is likely caused by a virus. Or doctors who prescribe antibiotics just because patients demand them. Or people who use leftover antibiotics given to them by friends and relatives. Or people who fail to finish the entire dose of a prescription, allowing the “toughest” germs to survive and reproduce.
Many experts believe that antibiotics given to animals also contribute to the development of resistance in humans and that the use of antibacterial soaps is another problem.
Just the other day, a patient came to see me with an infection on her chest. When I mentioned MRSA, it scared her. “Is it that bad bug I’ve heard about?” she asked. I told her “yes” but was able to add, “This is still something we can take care of.” The question is, how long will that be true?
HOW TO PROTECT YOURSELF:
► Know the signs of MRSA. A staph infection may appear as a boil, bump, or insect bite.
► See your doctor if a skin lesion becomes red, warm to the touch, is filled with pus, painful, or accompanied by a fever.
► Wash your hands regularly. Plain soap and water or alcohol-based gels (with at least 60% alcohol) are enough.
► Do not share personal items, such as towels or razors.
► Cover all cuts and scrapes with a bandage until they heal, especially if the wound oozes pus.
MRSA, a drug-resistant germ, lurks in Washington hospitals, carried by patients and staff and fueled by inconsistent infection control. This stubborn germ is spreading here at an alarming rate, but no one has tracked these cases — until now.
By Michael J. Berens and Ken Armstrong
Seattle Times staff reporters
What is MRSA? MRSA — methicillin-resistant Staphylococcus aureus — is an antibiotic-resistant form of the common staph germ. It survives on most any surface but thrives on moist areas of the skin. Over time, it has gained more resistance to antibiotics and developed strains tougher to treat.
How it's transmitted. It is spread by touch or contact. The pathogen enters the body through breaks in the skin, such as a cut or during surgery. Minor skin infections, such as blisters and boils, are the most common symptom. But the bacteria can develop into serious, even life-threatening, problems such as infections of the heart, blood and bones.
Where people get it. About 85 percent of people infected with MRSA get the germ at a hospital or other health-care facility. MRSA increasingly is spread in the community in such settings as playgrounds or locker rooms.
What you can do. Avoid sharing towels, razors and bar soap. Before having surgery, talk to your doctor about getting a MRSA test. Other preventive measures include washing hands and covering wounds with bandages.
Year after year, the number of victims climbed. But even as casualties mounted — as the germ grew stronger and spread inside hospitals — the toll remained hidden from the public, and hospitals ignored simple steps to control the threat.
Over the past decade, the number of Washington hospital patients infected with a frightening, antibiotic-resistant germ called MRSA has skyrocketed from 141 a year to 4,723.
These numbers don't appear in public documents. Washington regulators don't track the germ or its victims, and Washington hospitals do not have to reveal infection rates.
The Seattle Times analyzed millions of computerized hospital records, death certificates and other documents to track the swath of one of the nation's most widespread, and preventable, epidemics.
In its investigation — the first comprehensive accounting of MRSA cases in Washington hospitals - The Times gained access to state files that revealed 672 previously undisclosed deaths attributable to the infection.
MRSA, methicillin-resistant Staphylococcus aureus, is spread by touch or contact. It can slip into breaks in the skin as tiny as a mosquito bite.
Six out of seven people infected with MRSA contract it at a health-care facility.
Many people first learned about the germ last fall when the federal Centers for Disease Control and Prevention set off a media frenzy with its announcement that invasive MRSA infections claim at least 18,000 lives a year, more than AIDS.
But MRSA has been quietly killing for decades. And all along, there has been a simple diagnostic test that could have saved countless lives. This quick and painless test, which costs about $20, lets hospitals know who's infected or a carrier. Once identified, people with the germ can be isolated from other patients and treated.
Federal veterans hospitals screen all patients for MRSA, which has reduced their cases to near zero. Yet not a single community hospital in Washington screens every patient for the pathogen.
Many hospital officials say widespread screening is unnecessary and too burdensome. They say broad infection-control measures, such as washing hands and wearing protective garments, can thwart MRSA's spread.
But Washington hospitals violate these fundamental safety measures time and again, state and federal inspection reports reveal, from the Tacoma surgeon who refused to wear a mask during surgery to a Spokane blood technician who carelessly brushed her contaminated hands against supplies destined for other patients.
At Harborview Medical Center in the early 1980s, 17 people died during a MRSA outbreak fueled by the failure of the state's premier trauma center to isolate all infected patients immediately. But to this day, according to confidential records obtained by The Times, Harborview still rooms some MRSA patients with those who don't have the germ.
Meanwhile, MRSA is infecting and killing more people this year than ever before.
In October 2005, Joyce Allen went in for open-heart surgery at St. Joseph Medical Center in Tacoma. Doctors told her to expect a quick recovery. But during the operation, MRSA slipped into her chest. Doctors had cut through her sternum, a flat bone that binds the rib cage and protects the heart. When they fused the sternum back together, the contagion was entombed inside.
The blood-rich bone marrow was a perfect hiding spot. Within a week, the germ pushed into her arteries and crept into vital organs.
Physicians resorted to their most powerful antibiotic — vancomycin — known as the "drug of last resort." For six weeks, twice a day, Allen received intravenous infusions. A suction system sealed her chest and drained away toxic fluid.
"The pain was excruciating. I wanted to die, it hurt so bad," Allen says.
Antibiotics failed to conquer the infection. By April 2006, as Allen hovered near death, surgeons made the decision they had dreaded: Cut out the sternum.
They sheared away 6 inches of bone with a diamond-coated blade. Then they severed her abdominal muscles near the groin, and stretched the flaps tight across her chest, to shield her heart.
Allen, 57, is crippled for life. She measures each day by the level of pain. On her worst days, she's unable to pick up her small grandson.
"This germ destroyed my life," she says.
Disabled, she gave up her customer-service job at a Tacoma cabinet company. She now lives in a trailer in Spanaway, surviving on $877 a month in government benefits.
Nobody knows how the germ got into St. Joseph's operating room.
Allen says her surgeon was devastated by the infection. Hospital officials suggested that she might have carried the pathogen into the facility, on her skin.
If that were so, screening likely would have detected the germ and allowed doctors to eradicate it beforehand.
Cardiac patients like Allen are among the most vulnerable to MRSA infections and often face prolonged and expensive recoveries, medical research shows.
But St. Joseph didn't test her for MRSA, according to medical records. When it comes to most cardiac patients, the hospital still doesn't. On Friday, it said that policy is under review.
Who gets tested for MRSA, and who does not, is a medical game of chance.
Washington hospitals make their own rules. There are no federal or state mandates for screening.
The result is a haphazard array of infection-control policies that often fail to protect the most vulnerable patients, according to a Times survey of the state's 25 largest hospitals.
MRSA infections often strike critically ill patients or those with weakened immune systems — patients typically treated in a hospital's intensive-care unit.
But Swedish Medical Center in Seattle doesn't routinely screen patients in its ICU. Instead, it screens patients having elective surgery.
Sacred Heart Hospital in Spokane does test ICU patients — but not those seeking elective surgery.
The University of Washington Medical Center tests only premature babies.
Valley Medical Center in Renton doesn't routinely screen any patient group.
The bottom line is that most Washington patients don't get tested.
Whether to test, and whom to test, are at the core of a bitter national debate within the U.S. health care system.
Those who oppose testing all patients often argue that it undermines patient safety to dedicate limited resources to just one germ.
The reality, they say, is that hospitals often lack the staff, lab resources or space to ramp up existing testing programs or isolate large numbers of patients.
Swedish Medical Center would be hard-pressed to screen its 41,000-plus admissions each year, officials said. Harborview Medical Center, the state's most crowded hospital, doesn't have enough private rooms to isolate every patient, officials said.
Some hospitals fear lawsuits. If they screened every patient, results would show who already had the germ upon admission — and who picked it up while in the hospital. Patients could then blame the hospital for their infections.
Federally funded researchers called MRSA a possible epidemic in the early 1980s, following a series of outbreaks in large hospitals nationally. Yet most Washington hospitals began limited screening only within the past three years, The Times found.
"Many hospitals have ignored MRSA for decades," said Dr. William Jarvis, who retired in 2003 from the federal Centers for Disease Control and Prevention, where he was once acting director.
MRSA can cause painful and treatable skin lesions or slip into the blood. About 1 percent of infections prove fatal, while many others result in crippling injuries.
No one knows how many people carry the germ on their skin. Nationally, medical researchers have estimated that it's 1 or 2 percent of the general population. Washington hospitals that have initiated selective screening have discovered significantly higher levels — up to 11 percent.
Some surgeons around Seattle so dread the pathogen that they order tests when hospitals won't.
MRSA cases hidden. To control an infection, health officials need to know where it's been. They need counts, patterns, examples. But in Washington, MRSA's tracks have largely been obscured.
The state Department of Health asks physicians or medical examiners filling out death-certificate forms to give not only the primary cause of death, but the "chain of events" — the "diseases, injuries, or complications" — that contributed. Without such detail, these forms, when compiled in a database, may miss signs of emerging threats to public health.
But omissions undercut these certificates' value.
In 2005, Brenda L. Smith, 47, of Puyallup, died at Swedish Medical Center/Providence in Seattle. For "final anatomical diagnosis," her autopsy lists, at the top, MRSA pneumonia. But her death certificate — which relied on the autopsy report — says only pneumonia, with no mention of MRSA.
That same year, Willie Pompey, of Everett, died at age 58. His death certificate lists kidney failure, but does not account for an underlying reason. Pompey received a kidney transplant in 2002 at Virginia Mason Medical Center, but, because of a post-surgical MRSA infection, his body rejected the new organ. On his death certificate, MRSA is nowhere to be found.
How many examples are there like this? It's impossible to say. Finding them requires working backward — as The Times had to do — scouring lawsuits or other documents for indications of someone with MRSA, then comparing them against the public health records to see what, if anything, is missing.
A Bainbridge Island plaintiffs' lawyer, Christopher Otorowski, believes doctors may sometimes omit MRSA from death certificates because the infection is typically picked up in a hospital.
"Unless MRSA is the primary, explanatory cause of the death, I would think the physicians are going to be reluctant to put MRSA on the death certificate because it might implicate the hospital," he says.
For years, the state health department released a database of death certificates that is used by academics, journalists and others to report on public-health issues. But the state excluded a key component, a field that included doctors' notes that expanded on factors contributing to the person's death. The Times discovered the omission this year and insisted upon a complete database.
This new database links 672 deaths to MRSA between 2003 and 2006. The old database didn't attribute a single death to the germ. It couldn't have. The state relies on a standardized coding system, used internationally, that has more than 13,000 diagnosis codes — but not a single one for MRSA.
To gauge the prevalence of MRSA, The Times also analyzed a second database, which compiles diagnoses and billing records for patients discharged from Washington hospitals. The state uses this data, which has no individual names, to identify health trends and to analyze costs.
But as with the death certificates, this data set proved incomplete. The Times found dozens of examples where alternative records showed a patient had been treated for MRSA, while the billing database made no mention of it.
Because of these holes, the number of MRSA cases and deaths generated by the newspaper's analysis amounts to a minimum count, not a complete one.
Nationally, exact numbers are not available either, leaving public-health officials to estimate or extrapolate the scope of the epidemic.
Repeat offenders. To impede MRSA and other infectious germs, Washington hospitals typically rely on basic strategies — washing hands, isolating patients, sterilizing equipment.
But most of the state's 25 largest hospitals have been cited for unsanitary conditions or failure to adhere to fundamental safety standards, state and federal regulatory reports since 2005 show.
Last year, at Spokane's Holy Family Hospital, state Department of Health inspectors discovered the following:
A nurse entered Room 520 and dropped two packets of pills on the floor. Instead of throwing them out, she scooped up the packets and put them in a paper medication cup. She then pried the pills from the packets, dumped them into the contaminated cup and handed it to the patient.
An hour later, in a different room with an infectious patient, a staff member began to leave without washing hands. A second staffer tried to leave without discarding a contaminated gown. Both were headed for public areas of the hospital before state inspectors stopped them.
That afternoon, inspectors watched a phlebotomist draw blood from an infectious patient. Afterward, she brushed her gloved hands against items in a nearby supply cart — supplies destined for other patients.
In all, the four-day inspection cited seven staff members for violating basic infection-control standards, state records show.
Physicians can be the most lackadaisical about infection control.
In April 2006, doctors at the UW Medical Center carried personal items from home into sterile operating rooms and dropped them on the floor. These items included backpacks and satchels, made of porous materials friendly to germs. Hospital administrators told inspectors this was "common practice."
In November 2006, a physician at St. Joseph Medical Center in Tacoma removed his surgical mask during an operation. He had complained it was uncomfortable. Hospital officials told inspectors the physician was a "repeat" violator and had been warned before to keep his mouth and nose covered.
In hospitals, the most common violation is the failure to wash hands upon entering or leaving a patient's room.
In the worst cases, as few as 40 percent of staff members comply with hand-washing standards. Doctors are the worst offenders, according to confidential hospital records reviewed by The Times.
Even the best hospitals typically boast no better than 90 percent compliance — which means one out of 10 practitioners may have contaminated hands.
Hospitals remedied all violations spotted during the inspections, records show.
But these violations were all the more brazen because hospital officials — benefiting from a new law — knew the exact day that state inspectors were coming.
No surprise inspections. In the past, the state health department conducted surprise inspections to ensure that hospitals adhered to health and safety codes, from patient care to building maintenance.
But in 2002, the Washington State Hospital Association issued a 28-page report: "How Regulations are Overwhelming Washington Hospitals." In it, hospital administrators claimed surprise inspections disrupted patient care.
In Olympia, lawmakers voted unanimously to eliminate surprise inspections starting in July 2004. Today, the Department of Health must provide four weeks' notice — even the exact hour of arrival.
Hospital officials also had complained that some state inspectors were abrupt and unfriendly.
Lawmakers approved a Band-Aid: Hospital officials now can anonymously evaluate state regulators on whether they were polite enough.
The Legislature receives an annual compilation of these critiques. One hospital official wrote that state inspectors could "do a better job of highlighting the positive," instead of just looking for problems.
Washington is the only state that legally empowers hospitals to rate the conduct of regulators, according to the Consumers Union, a nonprofit organization that monitors hospital-related legislation.
"What kind of message does that send?" said Lisa McGiffert, who directs the organization's Stop Hospital Infections project.
Federally commissioned hospital inspectors began surprise inspections in 2004 — the same year Washington eliminated them.
The Joint Commission on Accreditation of Healthcare Organizations sets health-care standards and certifies hospitals to receive federal funding, such as Medicare. For decades, the commission had provided at least a month's notice before inspections.
But dozens of hospitals exploited the advance notice to temporarily hire more staff, cart in rental medical equipment — which was returned when inspectors left — and conduct dramatic makeovers with fresh sheets and pillows, according to inspector general reports at the U.S. Department of Health and Human Services.
Responding to public criticism, the commission stopped giving notice.
In some Washington hospitals, makeovers now take place just before state inspections, three registered nurses told The Times. The hospitals beef up staffs during planned inspections and, in some cases, have hired extra cleaners to disinfect beds and equipment, the nurses said.
The state hospital association recognizes "more needs to be done" to combat MRSA and is pushing to standardize patient-isolation procedures and increase hand-hygiene compliance, association president Leo Greenawalt said.
"My doctor was stunned"
When Chuck Velte first saw the woman at a flower show — sitting in a wheelchair, her right leg missing at the knee — he tried not to stare.
It was the spring of 2006, and Velte had knee surgery pending. He couldn't help but wonder: What happened to the woman's leg?
So he asked.
"She said that her knee was infected after routine surgery. She called the germ MRSA. I'd never heard of it," says Velte, who's now 64.
"I looked at her missing leg and was scared: This could be me."
Velte asked medical practitioners at Valley Orthopedic Associates in Renton about the germ's threat. He says they told him: Don't worry. This infection targets people with weak immune systems, and you're healthy.
Velte was unconvinced. A former senior analyst at Boeing, he launched into research. He learned patients could infect themselves if dormant MRSA germs were on their skin. The bacterium could drop into a wound during surgery and touch off numerous complications, even death.
Velte didn't know it, but at least 66 patients who underwent joint surgery the year before suffered amputation of legs, arms or fingers after contracting MRSA, a Times analysis of Washington hospital-billing records shows. For the past decade, the number of such patients stands at 512.
But Velte's research also turned up a simple safeguard: a nasal swab test that can detect if someone's a carrier.
Velte demanded to be screened. Doctors questioned its need, but sent him to a laboratory at Valley Medical Center in Renton, where the surgery was scheduled.
"I get there, and my knees are killing me, and the lab guys said they don't do a MRSA test. They told me to go home," Velte says.
Velte hobbled to the hospital's executive offices and plopped in a chair. "I want to see the highest-ranking person here," he recalls saying. "I'm not leaving here until I get a MRSA test."
An apologetic administrator arranged for a test. Results arrived four days later.
"I tested positive for MRSA," Velte says. "My doctor was stunned. He said that if he had operated, it could have been catastrophic."
To get rid of the germ, Velte scrubbed himself with over-the-counter soap containing chlorhexidine, an antibacterial chemical. He also wiped his house down with bacteria-killing bleach.
He was screened for MRSA again, was cleared and underwent surgery. It was successful.
A year later, MRSA invaded Velte's life again.
His 92-year-old mother, Rita, lived at a nursing home in Eau Claire, Wis. Last fall, Velte learned she had a festering wound, resembling a giant boil, on her buttocks. He demanded a MRSA test.
"After what I'd been through, I knew it was a possibility," he says.
A lab report confirmed his suspicions. His mother was infected with invasive MRSA, the worst kind. Within two days, she was gripped by pneumonia, followed by sepsis — blood poisoning — which reached into every vital organ, medical records show.
She suffered a fatal heart attack on Nov. 1 — less than two weeks after she was diagnosed with the germ.
Yet, MRSA did not appear on her death certificate. The official causes of death were heart attack, pneumonia and sepsis.
Velte says he demanded a correction — the truth. After reviewing medical records, the certifying doctor added MRSA.
"I wonder," Velte says, "how many people die of MRSA and nobody ever knows."
by Laura Landro
Wall Street Journal
Shortly after being admitted to a Cleveland-area hospital with severe abdominal pain, 52-year-old Maureen O'Hearn was transferred to intensive care. An intestinal infection had distended her abdomen so badly she appeared to be six months pregnant. To save her life, a surgeon had to remove her colon.
The cause of Ms. O'Hearn's illness was an epidemic strain of Clostridium difficile -- C. diff for short -- that is fast emerging as one of the most dangerous and virulent foes in the war against antibiotic "superbugs." C. diff is spawning infections in hospitals in the U.S. and abroad that can lead to severe diarrhea, ruptured colons, perforated bowels, kidney failure, blood poisoning and death.
Katie Lancey follows special procedures for cleaning a patient's room at SSM St. Joseph Hospital West in Lake Saint Louis, Mo.
Even as hospitals begin to get control of other drug-resistant infections such as MRSA, a form of staph, rates of C. diff are rising sharply, and a recent, more virulent strain of the bug is causing more severe complications. The Centers for Disease Control and Prevention estimates there are 500,000 cases of C. diff infection annually in the U.S., contributing to between 15,000 and 30,000 deaths. That's up from roughly 150,000 cases in 2001.
"We've been trying to sound the alarm repeatedly since 2004 that the trend is continuing upward," says Cliff McDonald, a CDC epidemiologist. He adds that C. diff, once mainly a concern for older patients, is now a growing risk for pregnant women, children and healthy adults.
Many patients get C. diff infections as an unintended consequence of taking antibiotics for other illnesses. That's because bacteria normally found in a person's intestines help keep C. diff under control, allowing the bug to live in the gut without necessarily causing illness. But when a person takes antibiotics, both bad and good bacteria are suppressed, allowing drug-resistant C. diff to grow out of control.
As a result, hospitals are more closely monitoring and limiting their use of antibiotics. It's a strategy that also has shown some success in preventing the spread of other drug-resistant bacteria. Once patients do contract a C. diff infection, hospitals sometimes can treat them with certain "last ditch" antibiotics, such as vancomycin, but many patients relapse after treatment.
Other efforts to stop the spread of C. diff include isolating infected patients; suiting workers and visitors from head to toe with scrubs, masks and gloves; and blasting patient rooms with super-strength bleach solutions. Milder "green" cleaners don't kill C. diff, undermining some hospitals' efforts to use these products.
One problem: C. diff produces spores that can dry out after cleaning and hang around on hospital cart handles, bed rails and telephones for months. Hand cleaning with alcohol, many hospitals' standard practice for keeping staff from spreading infection, can actually help disperse C. diff spores. Many hospitals now have special rules requiring staff to wash their hands with antibacterial soap when dealing with C. diff patients.
Clostridium difficile spores can last a long time and make the bug hard to kill.
Katie Lancey, lead environmental services aide at SSM St. Joseph Hospital West in Lake Saint Louis, Mo., says she spends up to an hour cleaning a room after a C. diff patient leaves. She wears protective garments and wipes down everything in the room with a bleach solution, including the TV, pillows, mattress and lower structure of the bed. "Anything you can think of, you make sure you wipe it down thoroughly," she says.
If a patient coming in to SSM St. Joseph is suspected of having C. diff infection -- severe diarrhea is one symptom -- they are put in isolation even before lab tests come back, says James Hinrichs, the infectious-disease specialist charged with the hospital's C. diff-prevention program. He says that when C. diff patients are discharged, he advises them to eat yogurt with so-called pro-biotics to help restore a healthy balance of bacteria in their intestines. He also tells families to follow strict cleaning and hand-washing rules at home.
The efforts, along with more careful use of antibiotics, have helped SSM St. Joseph reduce the rate of C. diff infections to 0.5 cases per 1,000 patient days currently from 2.5 cases in 2006, Dr. Hinrichs says.
C. diff was first recognized in the 1970s, when it was readily treatable. The more virulent strain was first identified at the University of Pittsburgh Medical Center in 2000, killing 18 patients. By 2004, the new C. diff strain was reported elsewhere in the U.S. and around the world, and studies showed it was producing 20 times more toxin than older strains.
Carlene Muto, medical director of infection control at the University of Pittsburgh, says the hospital was able to reduce its C. diff infections by 50% after the 2000 outbreak and has sustained that rate since then. It instituted strict cleaning practices, restricted its use of antibiotics and began relying on its electronic medical-record system to quickly flag lab tests of patients most at risk so they can be isolated. "You have to be constantly vigilant," Dr. Muto says.
Only 3% to 5% of healthy, non-hospitalized adults carry C. diff in their gut, but that rate is much higher in hospitals and nursing homes, where carriers can spread the bacteria to others. Studies at several hospitals in recent years have shown that 20% or more of inpatients were colonized with C. diff, and a 2007 study of 73 long-term-care residents showed 55% were positive for C. diff. Even though the majority had no symptoms of disease, spores on the skin of asymptomatic patients were easily transferred to the investigators' hands.
The CDC is launching a national surveillance effort to gather more precise data about the prevalence of C. diff. It is working with states to identify local outbreaks. It also is working with Medicare and the Environmental Protection Agency to develop new guidelines for fighting C. diff.
Nursing Home Infections
Ms. O'Hearn, the Cleveland-area patient, says she took an antibiotic for a sinus infection and then visited a nursing home, where she may have picked up the C. diff bug. During her hospital treatment, Ms. O'Hearn says she suffered an irregular heartbeat and dehydration, and required additional surgery to temporarily attach her small intestine to the abdominal wall to bypass the large intestine. "It was the worst nightmare that anyone could imagine," says Ms. O'Hearn, a nurse by training. Though she has returned to work and a more normal lifestyle, she continues to have digestive troubles, and must take medications to regulate her heart.
Kettering Medical Center near Dayton, Ohio, had 305 cases of C. diff last year and has had 165 cases so far this year. Even newborn babies have gotten the disease from their mother during birth, says Rebekah Wang-Cheng, Kettering's medical director for clinical quality. She says that among other measures, the hospital has cut its post-operative antibiotic doses for all joint-replacement surgeries to two from three to avoid C. diff infections. Patients who come into the hospital with suspected pneumonia now get an antibiotic within six hours, instead of four hours previously, to allow more time to assess the need for drugs.
One controversial strategy: fecal transplants. For one patient with recurrent C. diff, Kettering suggested a stool transplant from a relative, to help restore good bacteria in the gut. But Jeffrey Weinstein, an infectious-disease specialist at the hospital, says the patient "refused to consider it because it was so aesthetically displeasing."
The Greater New York Hospital Association in March began a 40-hospital effort to halt the spread of C. diff from patient to patient. This included placing signs on patient rooms with pictures of a bottle of bleach and soap and water to remind staff the room needs special cleaning. The association also asks visitors not to use patient bathrooms.
Hospitals face growing legal concerns if they don't take such measures; relatives of 16 patients who were infected or died from a C. diff outbreak are suing a Quebec hospital, claiming that infection-control practices weren't followed.
C. diff infections can emerge days or weeks after antibiotic therapy. Earlier this year, Marcus Glover, a 40-year-old mailroom worker for the Greater New York Hospital Association, was discharged from hospital after a successful rotator-cuff surgery, which included antibiotic treatment. Ten days later, he landed in an emergency room with a C. diff infection that required another week in the hospital. Mr. Glover avoided the worst complications and was successfully treated with strong antibiotics.
But C. diff can be fatal. Philadelphia radio personality Hy Lit, 73, contracted a C. diff infection at a rehabilitation center after being treated at a hospital owned by Main Line Health System last fall. He died in another Main Line hospital two weeks later. "It was a multiple train wreck, when the bug permeated his bloodstream and his kidneys failed," says his son, Sam Lit. "It was a tragedy to lose him like that."
Main Line says it can't comment on individual patients but adds that it follows stringent prevention guidelines and is conducting ongoing initiatives to control infections in its hospitals.
Wall Street Journal
Posted by Jacob Goldstein
With all the attention on antibiotic-resistant staph, or MRSA, you may have overlooked Clostridium difficile, the nasty bacterium behind a growing number of hospital-acquired infection. Turns out C. diff is infecting more than 1 in 100 inpatients, a nationwide survey just found.
APIC, the big infection-control group, asked its members to take a one-day snapshot of C. diff in U.S. hospitals; responses came back from more than 600 facilities in 47 states.
A day in the life of C. diff proved sobering. Thirteen of every 1,000 hospitalized patients are colonized with C. diff, and 94% of those patients show signs of C. diff disease, such as severe diarrhea. The finding suggests that, on any given day, some 7,000 hospital patients have C. diff, and about 300 will go on to die of the disease, the authors wrote.
The one-day-snapshot method is somewhat unusual, so it’s tough to compare these findings with C. diff numbers from earlier studies. But by any measure, it’s clear that C. diff is a growing problem. Check out this analysis, which found that the percentage of hospital patients with C. diff doubled between 2000 and 2005.
C. diff has the nasty habit of flourishing after patients are treated with broad-spectrum antibiotics, which wipe out the intestinal bacteria that normally keep C. diff in check. And it forms hardy spores that are difficult to kill — alcohol-based disinfectant gels, for example, don’t do the trick. What’s more, a recently discovered strain called NAP1 is not only especially virulent, but also appears to pass more easily from person to person than other strains of C. diff.
So what can be done? Solid isolation and hygiene by hospital personnel helps. So does avoiding broad-spectrum antibiotics when possible, and keeping the course of treatment short. For more tips, see this WSJ story.
November 11, 2008
The Association for Professionals in Infection Control and Epidemiology, Inc. (APIC) National Prevalence Study of Clostridium difficile in U.S. Healthcare Facilities
OVERVIEW AND KEY FINDINGS
A BRIEF HISTORY OF CLOSTRIDIUM DIFFICILE
Clostridium difficile (CD) is a spore-forming, gram-positive bacillus that produces exotoxins that are pathogenic to humans. CD is associated with a spectrum of diseases ranging from asymptomatic colonization to severe diarrhea, colitis, toxic megacolon, sepsis and death. Over the past 30 years, CD initially slowly and more recently rapidly emerged as an important healthcare-associated infection (HAI) pathogen.
Currently, CD is the most common cause of infectious healthcare-associated diarrhea, occurring in about 20% of hospitalized patients with antibiotic-associated diarrhea. A variety of studies have attempted to determine the “true” incidence/prevalence of CD. Archibald et al showed in 2001 that 12.2 CD infections [CDI] per 10,000 patient-days (incidence study) occurred in the Centers for Disease Control and Prevention (CDC) National Nosocomial Infections Surveillance (NNIS) system’s hospital ICU patients.
McDonald et al analyzed National Hospital Discharge Survey (NHDS) data and found that CDI incidence rates increased from 31 per 100,000 hospital population in 1996 to 61 per 100,000 hospital population in 2003.
A variety of factors are coalescing to potentially cause an increase in CDI. This includes the aging of the U.S. population, the widespread use of broad-spectrum antimicrobials, inadequate healthcare environmental cleaning, and inadequate CDI infection control measures (e.g., delayed diagnosis, delayed isolation precautions, poor hand hygiene or environmental cleaning). These factors, together with the recent emergence of a more virulent strain of C. difficile, the North American Pulse-field type 1 (NAP1) strain, makes it even more urgent that we have a better estimate of the magnitude of CDI in U.S.
Thus, in May 2008, we initiated the Association for Professionals in Infection Control and Epidemiology, Inc. (APIC) National Clostridium difficile Prevalence Survey. In this survey, we asked infection preventionists at APIC member healthcare facilities to determine on one day during the period of May - August, 2008, all CDI patients who were inpatients in their facilities. From this, we could calculate the true prevalence of CDI at these facilities and make estimates of the magnitude of CDI at U.S healthcare facilities.
APIC’s National C. difficile Prevalence Study is the largest, most comprehensive of its kind and provides valuable new information about C. difficile infections/colonization in U.S. healthcare facilities. The survey asked infection preventionists (primarily APIC’s 12,000+ members in the U.S.) to collect data about all patients in their facilities who were identified with C. difficile infection or colonization on one day during May-August, 2008.
So in a sense, this survey is a “snapshot” of C. difficile prevalence in the U.S. C. difficile infected/colonized patients were identified using microbiologic, medical, infection control, and/or other types of healthcare facility records.
Survey results include responses from 12.5 percent of all acute care hospitals in the United States (648 facilities – mostly acute care)
Responses were received from facilities in 47 states
Responses were received from facilities caring for virtually every type of patient: acute care, cancer, cardiac, children's, long-term care, rehabilitation facilities. In addition, they included county, private, and public facilities.
Responses were received from all sizes of facilities/hospitals: <100, 100-300, and >300-bed facilities
Survey includes data on both C. difficile infection and colonization.
TOP SURVEY RESULTS
1. Data shows that 13 out of every 1,000 inpatients in the survey were either infected or colonized with C. difficile (94.4% infected). This rate is 6.5-20 times higher than previous incidence estimates that were more limited in scope (one hospital or hospitals in one state and used different methodologies).
The total number of patients identified with C. difficile colonization/infection was 1,443.
Of those 1,443, the following detailed data was provided for 1062 (73.5%) of the patients:
• 55.9% were female, 44.1 % were male
• 84.7% were on the medical service
• 69.2% were >60 years of age
• 67.6% had co-morbid conditions (renal failure, diabetes, or heart failure)
• 57.9% had an initial episode of mild or moderate disease
• 10.94% had severe to complicated disease
• 89.8% of patients were detected by enzyme-linked immunoassay for A and B toxins (rather than culture)
• 1.98% were detected by culture
• 54.4% were detected <48 hours of admission
• 45.5% were detected >48 hours of admission*
• 72.5% were considered healthcare-associated infection
• 26.6% required ICU admission, 18.2% had shock, and 16.5% required vasopressors.
• 35.1% had long-term facility residence within 30 days of onset
• 79.4% had antimicrobial exposures before onset. (17.14% as surgical prophylaxis)
• 47.4% had hospitalization within 90 days of onset
• 46.5% had resolution of diarrhea within 6 days (CDC definition of cure)
(*many papers in the literature divide HA-C. difficile infection (CDI) from CA-CDI using this artificial cut- off of hours after admission, ignoring the fact that many patients are repeatedly admitted and thus become colonized with C. difficile at one admission and then are detected with infection at a subsequent admission.)
If the only U.S. hospital CDI patients were those reported in the survey (1,443 patients):
– Cost: $3.5 million - $10.4 million, average: $6.5 million (based on published rates ranging from $2,454-$7,179 cost per patient)
– Extra hospital days: 5,195 days - 10,101 days, average: 8,081 days (based on published rates ranging from 3.6 to 7 extra days per patient)
– Mortality: 33-88 patients, average: 61 patients (based on published rates ranging from 2.3-6.1 percent).
Extrapolating the impact to all inpatients on any one day:
Based on the average number of U.S. hospital inpatients (using 2006 AHA data of approximately 547,945 inpatients on any day) and our CDI rate (13/1,000 inpatients), we estimate:
– 7,178 CDI patients as inpatients in U.S. hospitals on any one day
– Cost: $17.6 million-$51.5 million, average: $32.1 million
– Extra hospital days: 25,841 - 50,246, average: 40,197 days
– Mortality: On any one day, the number of patients that would die from CDI would range from 165 to 438 with an average of 301.
54.4% of those with C. difficile in the survey were identified within 48 hours of hospital admission, which means that over half of the C. difficile infected patients are being admitted to the hospital/healthcare facility already infected or colonized with the
bug, having acquired it either in a previous healthcare facility stay or in the community at large.
Only 1.98% of C. difficile infected patients were identified by culture and only 4.2% of healthcare facilities routinely perform cultures for C. difficile. This means that most of the patients with C. difficile infection are detected by immunologic means and that their isolates are not available for further testing, e.g., antimicrobial susceptibility or genotyping to detect the NAP1 strain.
84.7% of all C. difficile infected patients were on the medical services, meaning they were being treated for general medical conditions like diabetes and pulmonary and cardiac problems.
79.4% of C. difficile infected patients received antimicrobials before their CDI onset. A wide variety of antimicrobials were associated with CDI. Furthermore, a wide variety of treatment regimens were used to treat the CDI.
Detailed data on the facilities that participated in the survey include:
• There was an average 1.5 infection preventionists at participating facilities
• Of participating healthcare facilities, 65.3% were urban and 34.7% rural
• Facilities had a median of 224 licensed beds and ranged in size from 6-1097 licensed beds
• Facilities had a total of 110,550 inpatients during survey period, averaging 171 patients per facility
• 26.5% of facilities were medical school affiliated and 24.4% were tertiary care facilities
• Most used a hypochlorite solution for environmental disinfection
• 46.7% reported having an antimicrobial stewardship program (62% of medical school affiliated and 41% of non-medical school affiliated facilities.).
**Costs based on published rates ranging from:
Cost (per patient):
$3,669 (Kyne CID 2002;34:346-53)
$2454-$3240 (hospital only) (Dubberke CID 2008;46:505-506)
$5142-$7119 (180 days) (Dubberke CID 2008;46:505-506)
$5325 (excess) (Lawrence ICHE 2007;28:123-30)
Minimum-maximum (Average): $2454-$7179 ($4475)
**Extra days based upon published rates:
Extra hospital length of stay:
3.6 days (Kyne CID 2002;34:346-53)
7 days (Vonberg JHI 2008;70:15-20)
6.1 days (Lawrence ICHE 2007;28:123-30)
Minimum-maximum (Average): 3.6-7 (5.6) days
**Mortality based on published rates:
2.3% (overall unadjusted) (Zilberberg EID 2008;14:929-931)
6.1% (ICU CDAD) (Kenneally Chest 2007;132:418-24)
The life-threatening bacterium that causes diarrhea and more serious intestinal conditions, Clostridium difficile, is sickening many more patients than previously estimated, according to a new study released by the Association for Professionals in Infection Control and Epidemiology (APIC).
“The National Prevalence Study of Clostridium difficile in U.S. Healthcare Facilities” indicates that 13 out of every 1,000 inpatients were either infected or colonized with C. difficile. Based on this rate, it is estimated that there are at least 7,178 inpatients on any one given day in American healthcare institutions with an associated cost of $17.6 to $51.5 million. The rate is 6.5 to 20 times greater than previous incidence estimates, according to the survey, released at APIC’s conference, “Clostridium difficile: A Call to Action,” in Orlando, Florida.
The APIC survey, the largest, most comprehensive of its kind, presents a one-day snapshot in time of the prevalence of C. difficile infection (CDI) in American hospitals. APIC’s 12,000 members collected data about all of their CDI patients on one day between May and August 2008. Survey results were collected from 12.5% of all medical facilities in the U.S. that care for virtually every type of patient, including those at acute care, cancer, cardiac, children’s, long-term care and rehabilitation hospitals. A total of 1,443 patients were identified with CDI from among the 648 participating hospitals.
CDI is most frequently associated with previous antibiotic use and is most commonly contracted by the elderly and those with recent exposure to hospitals, nursing homes and other healthcare institutions. It is transmitted by hand contact with items contaminated by feces. In the last five years, a more virulent and antibiotic-resistant strain has developed which has been associated with more serious disease, treatment failures and deaths.
“This study shows that C. difficile infection is an escalating issue in our nation’s healthcare facilities,” said William Jarvis, MD, principal investigator of the study and president and co-founder of Jason and Jarvis Associates, a private consulting firm in healthcare epidemiology. “ Clearly, preventing the development and transmission of CDI should be a top priority for every healthcare institution.”
According to the survey, 54.4 percent of patients with CDI were identified within 48 hours of admission and 84.7 percent were on the medical services, meaning they were being treated for general medical conditions like diabetes, pulmonary or cardiac problems and were on wards throughout the hospital.
“Our results show that the majority of CDI patients are admitted to the hospital already infected,” said APIC 2008 President Janet E. Frain, RN, CIC, CPHQ, CPHRM, Director, Integrated Services, Sutter Medical Center in Sacramento, CA. “Hospitals need to be looking for patients with severe diarrhea, and if CDI is suspected, promptly institute appropriate precautions such as gloves, gowns and separating patients, to avoid spreading the infection. Early recognition of CDI is critical so that prevention measures can be implemented.”
To reduce the risk of transmission, APIC has published a “Guide to the Elimination of Clostridium difficile in Healthcare Settings.” APIC recommendations include a risk assessment to identify high-risk areas for CDI within the institution; surveillance program to outline activities and procedures to provide early identification of CDI cases; adherence to CDC hand hygiene guidelines; use of contact precautions (e.g., gloves, gowns and separating CDI patients from other patients); environmental and equipment cleaning and decontamination, especially items that are close to patients such as bedrails and bedside equipment; and antimicrobial stewardship programs with focus on restriction of antibiotics associated with CDI and unnecessary antimicrobial use. APIC’s evidence-based elimination guides translate CDC recommendations into practice.
“Healthcare providers must intensify efforts toward developing prevention strategies that can be consistently applied across the continuum of care,” said APIC CEO Kathy L. Warye. “Control of CDI requires adequate numbers of infection preventionists and environmental services personnel, and prevention practices need to be part of everyone’s job within the institution. As part of our Targeting Zero initiative, APIC will continue to call for the commitment of clinical and administrative leadership to providing adequate resources for infection prevention programs to better protect patients in our nation’s healthcare facilities.”
The APIC National Prevalence Study of Clostridium difficile in U.S. Healthcare Facilities will be published in the American Journal of Infection Control. For more information about the study, visit www.apic.org.
(Nov. 24) - A doctor operating on a 37-year-old Phoenix woman thought to have a brain tumor found something entirely different: a parasitic worm.
(Cut and paste LINK below to see the story on FOX)
ABC News reports that Rosemary Alvarez, who underwent the procedure last summer after experiencing difficulty swallowing and numbness in her left arm, had a tapeworm called Taenia solium inside her head.
It turns out Alvarez likely contracted the tapeworm at some point by eating food tainted with the feces of a person infected with the parasite.
With the exception of a numb feeling in the back of her head, Alvarez has recovered nicely since the operation and is back to living a normal life.
November 24, 2008
by Judy Benson
With her rosy cheeks and easy smile, Rebecca Lowe looks like the healthy person she has been for most of her 19 years.
Yet the young woman, who lives with her parents in Preston and is a second-year student at Three Rivers Community College, is recovering from a five-week bout with a potentially life-threatening intestinal infection that's becoming more prevalent in southeastern Connecticut as a new strain of an old germ spreads worldwide.
The bacteria, clostridium difficile, causes C-difficile colitis, often called “C-diff,” and is considered a “super bug” because of the potency of the toxins it emits, its persistence in the environment, the difficulty of treating it, its frequent recurrence and its resistance to certain commonly used antibiotics.
Nationwide, there were 301,200 cases of C-diff in hospitals in 2005, more than twice as many as in 2001, according to federal health data published in April. That number that doesn't include cases diagnosed and treated outside hospitals. The incidence is highest in the Northeast.
”I'm still not totally better,” said Lowe, who still takes medications for nausea, pain and stomach acid. “I lost about 20 pounds, and I still haven't really developed an appetite.”
The only food she feels like eating these days is Cinnamon Toast Crunch cereal and milk, though, on her doctor's advice, she plans to start adding yogurt and fresh fruits and vegetables soon. She is trying to finish out the semester at school, but catching up has been difficult and she may have to drop two or three of her four classes. She has returned to her part-time job at the Yankee Candle store at Mohegan Sun, though fatigue and abdominal pain are still a problem.
”The first day I went back to work, when I got done and back to my car I cried for a half hour, because I was so tired,” she said.
This new strain of C-diff apparently evolved to take advantage of the bacterial vacuum created in the gut when beneficial bacteria needed for proper digestion are killed off. The good germs essentially become collateral casualties to antibiotics taken for everything from sinus infections to bronchitis to urinary tract infections, and research shows most cases of C-diff occur either during or just after a patient has taken antibiotics. But more C-diff patients without previous antibiotic use or a hospital or nursing home visit have been seen in Connecticut over the last two years, said Alice Ghu, medical epidemiologist with the state Department of Public Health.
Lowe's case followed the more typical path. She was given two antibiotics to prevent infection just before gall bladder surgery Oct. 13 at Lawrence & Memorial Hospital. That left an empty space in her system for the C-diff, which could have been dormant in her intestines or acquired in the hospital, to flourish. Infection set in the next day with a fever, severe abdominal pain different from the surgical pain, and sudden, frequent diarrhea. Her mother, Cindy, said her daughter had used antibiotics only rarely while growing up.
”Here she is, a young person in her prime, and it knocked her out for a whole month,” Cindy Lowe said.
Lowe spent the next three days in an isolation room at L&M, with nurses, doctors and her family covered head-to-toe in disposable caps, gowns and gloves when they entered. She got intravenous fluid and electrolyte replacement and one of the two antibiotics effective against C-diff. Then she went home, but ended up seeking emergency care a few days later when her symptoms worsened again. She was put on the second, stronger antibiotic, vancomycin.
”C-diff is very resistant, and getting more resistant,” said Lowe's gastroenterologist, Dr. Eugene Sapozhnikov.
C-diff is more common and serious in older people with other health problems, but the fact that young, otherwise healthy people like Lowe are being sickened with it concerns public health officials.
From 1999 to 2004, mortality rates for C-diff have increased from 5.7 per million to 23.7 per million, noted a Centers for Disease Control report published a year ago, and it was part of the cause of death in recent months for at least one patient at The William W. Backus Hospital in Norwich, according to Robin Heard, clinical coordinator of the Epidemiology Department.
In severe cases, C-diff patients have had surgery to remove portions of severely damaged bowel, and a new treatment involving enemas of fecal transplants from family members has been tried in a limited number of cases elsewhere in the country. The idea behind the treatment is to recolonize the colon with a complex array of healthy intestinal bacteria.
Dr. Joseph Gadbaw, chief of the department of medicine at L&M, said the emergence of this highly toxic, resistant strain of C-diff is further evidence of what many doctors and others have been saying for years: overuse of antibiotics is only teaching the bad germs how to become even worse.
Transmitted person-to-person or by contact with a contaminated surface, C-diff isn't killed by many routine disinfectants or by sanitizing hands with alcohol-based products like Purel. It can survive on tables, counters and bathrooms for months. To control its spread, L&M and other hospitals have switched to a bleach-and-water solution for cleaning that has been shown to be effective, Gadbaw said. Thorough and frequent handwashing with soap and water must be used instead of Purel for anyone in contact with C-diff patients, he added.
Heard, of Backus Hospital, said while there's no local epidemic of the disease, some noteworthy trends may be emerging. In the last year, the hospital's lab confirmed 160 cases of C-diff both among patients seen and treated at private doctors' offices and in the hospital.
Over that time, Heard said, there have been more cases of community acquired C-diff, in which the patient had no recent direct or indirect contact with a hospital or nursing home. And most of the people getting it, she said, have been taking both the antibiotic Levofloxacin and a proton pump inhibitor like Prilosec. Used for heartburn, it neutralizes stomach acid and perhaps makes a more hospitable environment for C-diff.
”We started to notice it three or four months ago,” she said.
The hospital, she said, is preparing a notice to doctors in the community to use an alternative to Levofloxacin, particularly in patients taking heartburn drugs. Lowe noted that she was given Prilosec for the first time just before her surgery.
Some have also noted that C-diff bacteria can be found on some packages of ground hamburger, providing another possible route of entry into the human digestive system.
Heard said the overall message about C-diff is that “people need to be very, very careful about antibiotic use.” Anyone who is taking antibiotics and develops sudden, severe crampy diarrhea, she said, could have a case of C-diff that can rapidly worsen.
”It can move rather quickly, so you need to tell your doctor,” she said.
Results of a new government report recently released find that more children are dying from the flu because they also had diagnosed staph infections, a fact that makes it all the more important for kids to get their flu shot.
According to the data from 2006 to 2007, 73 deaths occured in children with both the flu and a staph infection, and officials are predicting that when the numbers are tabulated for this past flu season that the number will be higher.
In the majority of these cases, the children were healthy, and between 5 and 17 years of age.
Traditionally the flu will not kill a child, or a healthy adult for that matter, but when underlying health conditions are involved, the risk of serious problems can go up considerably.
Last year, the flu vaccine shot was not very effective, but despite this fact, health officials are urging Americans that it is worth it to get it.
“It’s an important message to say even healthy children develop complications and die almost before anything much can be done for them,” said Dr. Gregory Poland, a Mayo Clinic infectious disease specialist.
An estimated 20,000 children are hospitalized in the U.S. each year because of flu.
October 30, 2008
Seven babies and four employees at a suburban New York hospital have been diagnosed with MRSA.
Officials at St. John’s Riverside Hospital in Yonkers, N.Y., became aware of the problem after the newborns developed skin rashes consistent with the drug-resistant staph infection, wcbs880.com reported.
"We are assuming that all seven cases are connected," Jim Foy, St. John's Riverside Hospital President and CEO, told the news radio station. "The strain seems to be community acquired. It is a localized skin infection but again, any infection that comes from a hospital is something you're concerned with. You're supposed to get better when you come to a hospital, not have anything come and make it worse."
The first case was identified on Sept. 24 and the most recent case was found Sunday, according to Foy.
Since the outbreak, the maternity ward and nursery areas have been thoroughly scrubbed down and nurses and doctors have been asked to watch out for cases.
MRSA is an infection caused by a strain of Staphylococcus aureus bacteria that is highly resistant to antibiotics, the National Institutes of Health said on its Web site.
It’s a common bacteria that normally lives on the skin and sometimes in the nose. Infections occur with the bacteria enters the body through a cut or sore. Serious staph infections are most common in people with weak immune systems, usually patients in hospitals and long-term care facilities, according to the NIH.
WASHINGTON, Oct. 28, 2008: by Emily Walker, Washington Correspondent MedPage Today - The worst of the national Clostridium difficile epidemic is yet to come, researchers cautioned here. The current C. difficile epidemic strain, NAP1/027, has spread to all 50 states, said Clifford McDonald, M.D., of the CDC's Division of Healthcare Quality and Promotion.
And the epidemic is likely to get worse before it gets better, said others at the Interscience Conference on Antimicrobial Agents and Chemotherapy, held jointly with the Infectious Diseases Society of America (IDSA) meeting.
"I don't think we've peaked yet," said Lance Peterson, M.D., of the Evanston (Ill.) Northwestern Healthcare Research Institute.
C. difficile disease is thought to be the result of antibiotics that disrupt patients' normal gut flora, which makes them susceptible to the C. difficile bacteria on hands and hospital surfaces.
Discharge data showed a four-fold increase in C. difficile rates since 2001, when hospitals first began seeing a surge in patients being infected with the bacteria. Meanwhile, deaths caused by C. difficile have increased five-fold, said Dr. McDonald.
"The total burden of C. difficile infections probably exceeds 500,000 cases annually," said Dr. McDonald. "And from that, we're looking at at least 15,000 deaths caused by or contributed by C. difficile."
The IDSA, with the Society of Healthcare Epidemiology of America, recently published a practicum to prevent the spread of C. difficile, recommending, among other things, restraint when prescribing antibiotics, bleach to clean surfaces during outbreaks, and better hand-washing practices.
The NAP1/027 strain of the bacteria caused outbreaks in Canada during 2003 and 2004, leading to 700 deaths in Quebec province in one year. According to Jacque Pepin, M.D., of the University of Sherbrooke, the rates have now leveled off at about 400 deaths per year, but that's still four times the mortality rate from before the bacterial epidemic.
Current treatment hinges largely on two antibiotics -- vancomycin and metronidazole -- but the effectiveness of those drugs is waning, researchers said.
"[There has been] no improvement in 30 years, and we desperately need new therapies," said David Classen, M.D., of the University of Utah in Salt Lake City.
Slowing the C. difficile epidemic will take something more than current broad-spectrum antibiotic treatment, Dr. Pepin said.
That something may be a procedure called a "fecal transplant."
That is just what it sounds like: taking a fecal sample from a healthy relative of an infected person, filtering the sample, and infusing (usually via enema) the filtrate into the C. difficile patient.
In theory, whatever defenses were depleted from the infected person's intestines by antibiotic treatment will be restored through an infusion of healthy feces, said Dale Gerding, M.D., of Hines VA Hospital in Chicago.
The procedure is fairly rare, and is practiced just in Norway and several places in Canada. But it has led to success rates of about 90%, Dr. Gerding said.
Other future treatment options for C. difficile include developing a more focused, non-absorbable antibiotic that would target the gut and stay there, attacking the C. difficile bacteria while preserving the flora, said Dr. Gerding.
Dr. Classen said he is hopeful about a vaccine strategy, which he expects will move to human testing in early 2009, although Dr. Gerding said it would be "many years" before such therapies are available.
Jane Hansen | October 08, 2008
ANTIBIOTICS have been thrown at everything, from the most infectious diseases to the slightest cough. As well, in pursuit of higher profits, food producers have used them to fatten up chickens and pigs. As a result, bacteria are becoming immune to a depleted arsenal of the wonder drugs of the 20th century. And the golden era, in terms of controlling and curing illness and death caused by bacteria, is coming to an end.
David Paterson with E. coli at the University of Queensland; he says the bug produces an antibiotic-destroying enzyme.
"I've lived in the days before antibiotics, and they weren't pleasant," recalls Kathleen Calvert, a 71-year-old retired teacher based in Canberra. As a child she suffered dreadful middle-ear infections.
"You just had to endure the pain, wait for an abscess to form and then it would burst, time and time again, and I'm partially deaf in one ear as a result."
Then along came the miracle drug of the 20th century, penicillin, and Calvert finally rid herself of the ailment that had plagued her childhood. Now she is at the other end of the antibiotic golden age, battling a multi-drug-resistant bug she picked up in China.
"I have had a recurring urinary tract infection that flares up every six months, I can't get rid of it," she says of the common ailment that affects millions of women worldwide. For the past few decades, it has been treated by a simple three-day course of oral antibiotics, but those drugs are impotent against the strain Calvert acquired in Beijing.
"I've had four week-long intravenous courses with last-line antibiotics and it keeps coming back. I've felt like typhoid Mary. People avoid you and think they might be contaminated by you," Calvert says.
Sharing a bath towel with Calvert could pass on the infection, theoretically, but the bigger threat is that the rogue bacteria will swap its resistant gene with local bugs, giving birth to a home-grown resistant bug. There is good evidence this is happening.
"Bacteria are really good at having bacterial sex and swap their resistant genes at a rapid rate," says Peter Collignon, head of infectious diseases at Canberra Hospital and microbiologist with the medical school at the Australian National University.
Doctors believe travel to developing countries is one possible reason for the rapid emergence of drug-resistant E.coli and other gut bugs among healthy people who have had no previous contact with the hospital system.
Superbugs, those born and bred in hospital corridors in response to high antibiotic use, have plagued patients for years, but sister versions of these bugs are emerging at a rapid rate in the community, affecting the young and healthy.
"The doomsday scenario of a world without effective antibiotics is already playing out in countries like China," Collignon says. "They don't keep good data and the media is controlled, but people are dying regularly from complications of drug-resistant common bugs like E.coli, and golden staph, and tuberculosis."
Like most organisms, big and small, bacteria have forms of attack and defence, and some produce toxic substances that can kill other bacteria: we call them antibiotics. In response, other bacteria produce enzymes that can neutralise the antibiotics. The same battle is being waged on the human health front because of the overuse of antibiotics. And the resistant bacteria are winning.
Nasty bugs that cause tuberculosis have armed themselves to defy the drugs that cure often fatal ailments. A recent study published in The Medical Journal of Australia proved a multi-drug-resistant strain of tuberculosis, called MDR-TB, is already on our doorstep in the Torres Strait.
Of 60 patients from the Western Province of Papua New Guinea, 15 had MDR-TB and mortality was high. Islands of the Torres Strait are only 5km offshore and villagers visit each other frequently.
"It's a difficult ailment to treat at the best of times, requiring four separate oral antibiotics staggered over six months," says Christopher Coulter, one of the study's authors. "The MDR-TB needs 18 to 24 months of expensive oral and intravenous treatment with last-line drugs. The doomsday scenario is a return to the days where you can't treat it, which is already happening in South Africa."
The report calls for urgent intervention to stop the spread of MDR-TB to the mainland.
Next month, the federal Department of Health and Ageing in conjunction with Queensland Health will co-ordinate the building of a TB laboratory and clinical management project to diagnose and treat MDR-TB in PNG.
The other killer is the community version of resistant golden staph, or methicillin-resistant staphylococcus aureus. Once confined to hospitals, where it kills up to 2000 compromised patients a year, the community version emerged across the world at the same time in the late 1990s.
In Australia, the so-called Queensland strain has a flesh-eating toxin and it is more virulent than the hospital version.
"Not only does the community strain have a Kevlar vest on, it also has this Exocet missile attached that destroys flesh," Collignon says.
To glimpse the hellish world where antibiotics are powerless against such vicious bugs, you just have to walk into Julie Gray's Sydney home. The ashes of her "beautiful, strapping young son" Reis sit in a polished wooden box on the mantelpiece, his precious guitar in a stand nearby.
A year ago this month, Reis had what everyone thought was a bad dose of the flu. The GP gave him antibiotics, but after three days he was taken to hospital.
"I just didn't like the colour of his skin," Gray recalls.
"At the hospital they found his pulse was so low, they had to put him on life support. Before he closed his eyes he asked me, 'Will I be OK, Mum?' I said, 'Of course you will.' But he never woke up. I just never thought a simple bug could kill a healthy 16-year-old who'd never been to hospital in his life." He died from the community version of MRSA: the flesh-eating toxin "just ate his lungs", Gray says, shaking her head in disbelief.
Community-acquired MRSA causes boils and abscesses, but in rare cases it can go to the lungs and kill, Collignon says.
"That is a real worry when one in 10 staph infections are now attributed to community-acquired MRSA," he says.
Now E.coli, the most common germ known to cause infection in humans, also has become drug resistant outside hospitals.
"They can defy almost every antibiotic," says David Paterson, an infectious diseases consultant to the Royal Brisbane & Women's Hospital and a world authority on so-called gram negative bacteria such as E.coli. "The bug produces enzymes called beta lactamase and they physically destroy antibiotics."
The overuse of antibiotics throughout the world has caused the problem, especially in developing countries, where you can buy second and third-generation antibiotics - the so-called last-line antibiotics - over the counter. Farm producers also feed them to chickens and pigs.
"In the US and Brazil, every chicken, before it has even hatched, is injected with a third-generation antibiotic," Collignon says. "The antibiotics aren't in the food, the resistant bugs are. So food, if not washed or cooked properly, can become a source of contamination." Collignon proved his point by culturing his own faeces before and after a recent trip to China. Despite being fastidiously clean, what he ate produced a drug-resistant strain of E.coli on his return.
With the international trade in food, the bugs have spread. In the US in 2006, Paterson, then with the University of Pittsburgh's school of medicine, cultured bacteria from chickens bought in a variety of supermarkets. Most carried the enzyme that makes them drug resistant.
Australia does not import fresh chicken and recent attempts by food producers to do so were quashed. We do, however, import fresh fruit and vegetables.
In a 2007 Australian Quarantine Inspection Service imported food survey, 97 samples were tested for E.coli.
"E.coli was detected in 14 samples, mainly in exotic leaf crops. These leaf crops are usually washed and/or cooked prior to consumption. E.coli was also found in some vegetables: taro, baby corn, asparagus and mushrooms. Again, these vegetables are generally washed and/or cooked prior to consumption. Health authorities in Australia recommend washing and cooking vegetables as a risk-mitigation step for the presence of micro-organisms, including E.coli," the report says.
Food Standards Australia advised at the time that the levels of E.coli found in the products would not seriously affect human health. But they were there nonetheless.
The other big problem is that there is little or no investment in future antibiotics, Collignon says.
"Antibiotics are a bad investment for drug companies. For a start, they are drugs that cure, so it's much better from a drug company's perspective to pour money into drugs that control symptoms for things like diabetes and heart disease, drugs that patients have to take for life," Collignon says.
Says Paterson: "Then you've got doctors like Professor Collignon and myself telling everyone not to take these precious drugs, keep them in reserve unless absolutely necessary." Antibiotics have been the one true miracle drug, stopping people from dying in large numbers. But the miracle is fast fading. Paterson likens the present climate to the heady, hedonistic days of the late 1970s.
"It is like San Francisco and Sydney in the late '70s, when no one gave thought to any controls over what we might do if HIV came along, but when that horrific epidemic happened, for many people it was too late."
ORLANDO, Fla. - Three new cases of MRSA have been reported, bringing the total throughout central Florida into the double digits.
Many parents are very concerned; one parent said that they have considered removing their child from school and home-schooling them. "I don't want to say it's an epidemic, but there's a breakout in Central Florida," said concerned parent Shannon Elkins.
The staph infection has spread throughout Orange County schools with the total now at five. Orange County schools have been taking swift actions to prevent the infection.
Superintendent Ronald Blocker contacted parents with this recorded message: "Hello parents, this is Orange County Schools Superintendent Ron Blocker. Some of you may have heard recent news accounts of Central Florida children contracting MRSA, a skin infection caused by the common bacteria known as staph," said Blocker.
One case is at Dover Shores elementary.
Principal Dr. Randall Hart sent a letter home to reassure parents. "We should be concerned about it, but we are doing everything we can to make sure that it's controlled here," said the Hart in the letter.
Two other cases are at Memorial Middle school and Pine Hills Elementary.
Elkins said she does not have much faith in the schools' efforts in preventing MRSA so she is doing what she can to protect her child. "We're doing our part to make sure that he's taking care of as far as hand washing, and not touching other kids with open wounds," said Elkins.
So far there has been one case in Marion Co., one case in Volusia Co., five cases in Orange Co., two cases in Osceola Co. and four cases in Brevard Co.
The best way to prevent MRSA is to keep good hygiene, wash hands frequently and clean cuts and wounds.
Dr. Jaime Carrizosa specializes in infectious diseases.
He said the 13 cases of MRSA that have hit Central Florida are not a surprise. Carrizosa said things could get worse if it's not managed properly, and the number of MRSA cases keeps increasing.